A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma.

CONCLUSION: Our data showed that PHY906 increases the therapeutic index of capecitabine by enhancing its antitumor activity and reduces its toxicity profile in advanced HCC.
PMID: 33140457 [PubMed - as supplied by publisher]

Source: The Oncologist - November 3, 2020 Category: Cancer & Oncology Authors: Changou CA, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y Tags: Oncologist Source Type: research